MIST Milestone Pharmaceuticals | $2.56
+6.7% | +48.8%
 | Etripamil
For Treatment in Paroxysmal Supraventricular Tachycardia | | 7/11/2025 - FDA review
Milestone® Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has acce…
Full Summary |
MIST Milestone Pharmaceuticals | $2.56
+6.7% | +48.8%
| Etripamil
For Treatment in Paroxysmal Supraventricular Tachycardia | Target date: 2025-12-13 | 7/11/2025 - PDUFA Date
Milestone® Pharmaceuticals Inc announced that The FDA has assigned a new Prescription Drug User Fee…
Full Summary |
CAPR Capricor Therapeutics | $11.40
-0.2% | -13.2%
 | deramiocel
For the treatment of Duchenne muscular dystrophy (DMD) | BLA | 7/11/2025 - Complete Response Letter
Capricor Therapeutics announced that it has received a Complete Response Letter (CRL) from the U.S.…
Full Summary |
AGEN Agenus | $5.92
+14.3% | +14.7%
 | AgenT-797
Multiple myeloma | | 7/11/2025 - Publication
MiNK Therapeutics, Inc. announced the publication of another landmark case in Nature's Oncogene des…
Full Summary |
INKT MiNK Therapeutics | $7.73
+6.2% | +1.8%
 | AgenT-797
Multiple myeloma | | 7/11/2025 - Publication
MiNK Therapeutics, Inc. announced the publication of another landmark case in Nature's Oncogene des…
Full Summary |
BCTX Briacell Therap | $2.07
-1.9% | -40.7%
 | Bria-IMT
Metastatic breast cancer (breast cancer that has spread beyond the breast) |
Phase 2 | 7/11/2025 - Survival data
BriaCell Therapeutics Corp announced updated Phase 2 survival data for its lead immunotherapy candi…
Full Summary |
ONC BeOne Medicines | $253.39
-0.9% | -3.4%
 | Tislelizumab
Recurrent or Metastatic Nasopharyngeal Cancer | EC Approval | 7/10/2025 - Approved
BeOne Medicines Ltd. announced that the European Commission has approved TEVIMBRA® (tislelizumab), i…
Full Summary |
MRK Merck & Co., Inc. | $84.06
+0.4% | +4.7%
 | Doravirine/Islatravir
In adults with HIV-1 infection |
NDA | 7/10/2025 - FDA review
Merck announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Dru…
Full Summary |
PFE Pfizer | $25.77
+0.8% | +5.4%
 | XTANDI (Enzalutamide)
Metastatic Hormone-Sensitive Prostate Cancer |
Phase 3 | 7/10/2025 - Top-line results
Pfizer Inc. and Astellas Pharma Inc announced positive topline results from the overall survival (O…
Full Summary |
TNXP Tonix Pharmaceuticals | $42.36
+10.4% | +12.3%
 | TNX-801
Potential Vaccine to Prevent Mpox and Smallpox | | 7/10/2025 - Presentation
Tonix Pharmaceuticals announced the presentation of new findings on TNX-801 (recombinant horsepox,…
Full Summary |
STOK Stoke Therapeutics | $12.04
+0.2% | +4.7%
 | zorevunersen
For the treatment of Dravet syndrome with a confirmed mutation, |
Phase 3 | 7/10/2025 - Presentation
Stoke Therapeutics, Inc and Biogen Inc announced the presentation of data from an analysis that inf…
Full Summary |
CGTX Cognition Therapeutics | $0.70
+31.7% | +121.0%
 | CT1812
Designed to penetrate the blood-retinal barrier and bind selectively and saturably to the σ-2 receptor complex. |
Phase 2 | 7/10/2025 - FDA Meeting
Cognition Therapeutics, Inc., announced that it conducted an end-of-Phase 2 meeting with the U.S. F…
Full Summary |
BCTX Briacell Therap | $2.07
-1.9% | -40.7%
| Bria-IMT
Metastatic breast cancer (breast cancer that has spread beyond the breast) |
Phase 2 | 7/10/2025 - updated results
BriaCell Therapeutics Corp announced updated results from its ongoing Phase 2 study of Bria-IMT™ in…
Full Summary |
LGND Ligand Pharmaceuticals | $124.98
+2.1% | +8.3%
 | ZELSUVMI
For the Treatment of Molluscum Contagiosum | | 7/10/2025 - Provided Update
Pelthos Therapeutics Inc. announced the launch of ZELSUVMI™ (berdazimer) topical gel, 10.3%, for the…
Full Summary |
PDSB PDS Biotechnology | $1.30
-1.5% | -25.7%
 | PDS01ADC
For the treatment of recurrent prostate cancer | | 7/10/2025 - Provided Update
PDS Biotechnology announced patient recruitment has been completed in Stage 1 of a clinical trial o…
Full Summary |
ABOS Acumen Pharmaceuticals | $1.30
+4.0% | +14.0%
 | Sabirnetug
for Early Alzheimer's Disease | | 7/10/2025 - Presentation
Acumen Pharmaceuticals, will present new findings at the upcoming Alzheimer's Association Internati…
Full Summary |
RCUS Arcus Biosciences | $9.51
+1.9% | +4.6%
 | quemliclustat
For Pancreatic Cancer | Orphan Drug | 7/10/2025 - Designation Grant
Arcus Biosciences, Inc announced that quemliclustat, an investigational small molecule CD73 inhibito…
Full Summary |
AAPG Ascentage Pharma Group International | $40.74
-2.7% | +36.9%
 | lisaftoclax
In Venetoclax-Refractory Patients | NMPA Approval | 7/10/2025 - Approved
Ascentage Pharma announced that its proprietary novel Bcl-2 selective inhibitor lisaftoclax (APG-25…
Full Summary |
RGNX REGENXBIO | $9.06
-1.2% | -11.2%
 | RGX-202
Duchenne Muscular Dystrophy | | 7/10/2025 - Publication
REGENXBIO Inc. announced the publication of preclinical results comparing a microdystrophin gene the…
Full Summary |
LLY Eli Lilly and Company | $790.23
+0.4% | -2.2%
 | Kisunla
For the Treatment of Early Symptomatic Alzheimer's Disease | | 7/9/2025 - FDA approved
Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved a la…
Full Summary |
EXAS Exact Sciences | $53.32
-3.6% | -4.2%
 | Oncodetect™
Molecular Residual Disease Test | | 7/9/2025 - Provided Update
Exact Sciences Corp announced that its Oncodetect™ molecular residual disease (MRD) test has recei…
Full Summary |
KRYS Krystal Biotech | $149.74
+0.6% | +7.2%
 | KB801
For the Treatment of Neurotrophic Keratitis | Phase 1/2 | 7/9/2025 - Dose Update
Krystal Biotech, Inc announced that the first patient has been dosed in its Phase 1/2 clinical trial…
Full Summary |
RZLT Rezolute | $5.25
-0.6% | +20.7%
 | Ersodetug
For Hypoglycemia Due to Congenital Hyperinsulinism |
Phase 3 | 7/9/2025 - Abstract
Rezolute, Inc announced that the abstract titled "Preliminary Patient Demographics And Baseline Char…
Full Summary |
BCTX Briacell Therap | $2.07
-1.9% | -40.7%
| Bria-OTS
In metastatic breast cancer | | 7/9/2025 - Provided Update
BriaCell Therapeutics Corp announced the sustained complete resolution of lung metastasis in a patie…
Full Summary |
ALT Altimmune | $4.40
-7.2% | -32.7%
 | pemvidutide
for the treatment of obesity and MASH |
Phase 2 | 7/9/2025 - Enrollment Update
Altimmune, Inc. announced that it has enrolled the first patient in the RESTORE Phase 2 trial evalua…
Full Summary |
ARTL Artelo Biosciences | $28.50
+31.9% | +295.8%
 | ART26.12
For the prevention of chemotherapy-induced peripheral neuropathy, a debilitating and often treatment-altering side effect of cancer therapy. | | 7/9/2025 - Data Presentation
Artelo Biosciences, announced the presentation of preclinical data in an osteaoarthritis (OA) pain …
Full Summary |
BIVI BioVie | $7.57
-6.0% | -31.8%
 | Bezisterim
For Parkinson's Disease Patients | | 7/9/2025 - Provided Update
BioVie Inc. presented "Bezisterim Epigenetic Effects on Aging and Neurodegeneration" at the 7th Worl…
Full Summary |
EOLS Evolus | $9.73
+0.7% | -5.0%
 | Nuceiva®
For the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients2. | | 7/9/2025 - Provided Update
Evolus, Inc announced it has partnered with Symatese to commence distribution of Nuceiva® (botulinu…
Full Summary |
BHC Bausch Health Cos | $6.65
+0.8% | +24.8%
 | CABTREO
For the Treatment of Acne Vulgaris | | 7/9/2025 - Provided Update
Bausch Health, Canada Inc announced that PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl …
Full Summary |
KALA KALA BIO | $6.90
+9.5% | +57.5%
 | KPI-012
Clinical diagnosis of PCED | | 7/9/2025 - Enrollment Completion
KALA BIO, Inc. announced the completion of patient enrollment in the CHASE (Corneal Healing After SE…
Full Summary |
KALA KALA BIO | $6.90
+9.5% | +57.5%
| KPI-012
Clinical diagnosis of PCED | Target date: 2025-Q3 | 7/9/2025 - Top-line results
KALA BIO, Inc. announced that Topline results from the CHASE trial expected by end of Q3 2025 --
Full Summary |
RYTM Rhythm Pharmaceuticals | $89.04
+0.0% | +37.3%
 | bivamelagon
In patients with acquired hypothalamic obesity. |
Phase 2 | 7/9/2025 - Top-line results
Rhythm Pharmaceuticals, Inc. announced positive topline results from its Phase 2 trial evaluating bi…
Full Summary |
BHC Bausch Health Cos | $6.65
+0.8% | +24.8%
| PrCABTREOTM
For Treatment Of Acne Vulgaris | | 7/9/2025 - Provided Update
Bausch Health, Canada Inc., part of Bausch Health Companies Inc. announced that PrCABTREOTM (clinda…
Full Summary |
BNTC Benitec Biopharma | $13.79
-0.4% | -16.7%
 | BB-301
Oculopharyngeal Muscular Dystrophy (OPMD) | Phase 1b/2a | 7/9/2025 - Enrollment Update
Benitec Biopharma Inc. announced the recommendation of the independent Data Safety Monitoring Board…
Full Summary |
EVOK Evoke Pharma | $6.11
-12.6% | +103.7%
 | GIMOTI (metoclopramide) nasal spray
Acute and recurrent diabetic gastroparesis | | 7/9/2025 - Notice of Allowance
Evoke Pharma, Inc. announced that it has received a Notice of Allowance from the United States Pat…
Full Summary |
ELAN Elanco Animal Health | $15.06
+1.9% | +5.7%
 | TruCan™ Ultra
Canine Influenza Vaccine | | 7/9/2025 - Approved
Elanco Animal Health announced the U.S. Department of Agriculture (USDA) has approved TruCan Ultra …
Full Summary |
ASBP Aspire Biopharma | $0.35
+6.2% | -13.1%
 | BUZZ BOMB
New Sublingual Pre-Workout Supplement | | 7/9/2025 - Positive Feedback
Aspire Biopharma Holdings, Inc. announced positive initial consumer feedback from the Company's samp…
Full Summary |
MTVA MetaVia | $0.72
+3.9% | -4.6%
 | DA-1726
For The Treatment Of Obesity |
Phase 1 | 7/9/2025 - Dosing Update
MetaVia Inc. announced dosing of the first patient in the 48 mg, multiple ascending dose (MAD) coho…
Full Summary |
MTVA MetaVia | $0.72
+3.9% | -4.6%
| DA-1726
For The Treatment Of Obesity | Target date: 2025-Q4 | 7/9/2025 - Top-line data
MetaVia Inc. announced that Top-Line Data Expected in the Fourth Quarter of 2025
Full Summary |
CNTB Connect Biopharma | $1.15
+5.6% | +40.4%
 | Rademikibart
For Moderate-To-Severe Atopic Dermatitis |
NDA | 7/9/2025 - NDA Filing
Connect Biopharma Holdings Limited announced that the Company's collaborator and exclusive licensee…
Full Summary |
TNXP Tonix Pharmaceuticals | $42.36
+10.4% | +12.3%
| TNX-102 SL
Fibromyalgia |
Phase 3 | 7/9/2025 - Results
Tonix Pharmaceuticals announced that full results from its confirmatory Phase 3 RESILIENT trial of …
Full Summary |
RARE Ultragenyx Pharmaceutical | $31.03
-25.1% | -17.3%
 | UX143 (setrusumab)
Osteogenesis Imperfecta (OI) |
Phase 3 | 7/9/2025 - evaluation
Ultragenyx Pharmaceutical announced that the randomized, placebo-controlled Phase 3 portion of the O…
Full Summary |
MRK Merck & Co., Inc. | $84.06
+0.4% | +4.7%
| MK-8527
novel nucleoside reverse transcriptase translocation inhibitor | | 7/8/2025 - New Data
Merck announced that new data from its research pipeline for HIV prevention and treatment will be p…
Full Summary |
ETON Eton Pharmaceuticals | $15.56
-1.3% | +3.1%
 | ET-600
For the treatment of an endocrinology |
NDA | 7/8/2025 - FDA review
Eton Pharmaceuticals, Inc announced the Company's New Drug Application (NDA) for ET-600, a propriet…
Full Summary |
ETON Eton Pharmaceuticals | $15.56
-1.3% | +3.1%
| ET-600
For the treatment of an endocrinology |
NDA
Target date: 2026-02-25 | 7/8/2025 - PDUFA Date
Eton Pharmaceuticals, Inc announced that NDA has been assigned a Prescription Drug User Fee Act (…
Full Summary |
LRMR Larimar Therapeutics | $3.48
+0.6% | +12.3%
 | nomlabofusp
For Friedreich's Ataxia | | 7/8/2025 - Publication
Larimar Therapeutics, announced the publication of two peer-reviewed articles highlighting nonclin…
Full Summary |
EPRX Eupraxia Pharmaceuticals | $5.57
+2.0% | +41.8%
 | EP-104GI
For Treatment of Eosinophilic Esophagitis |
Phase 2b | 7/8/2025 - Dose Update
Eupraxia Pharmaceuticals Inc. announced the first patient dosed in the Phase 2b randomized, placebo-…
Full Summary |
UPB Upstream Bio | $11.84
+1.2% | +1.4%
 | Verekitug
In Chronic Obstructive Pulmonary Disease (COPD) |
Phase 2 | 7/8/2025 - Dose Update
Upstream Bio, Inc. announced that the first patient has been dosed in the Company's Phase 2 clinica…
Full Summary |
PSTV Plus Therapeutics | $0.35
-0.5% | +6.4%
 | REYOBIQ™
For Patients with Leptomeningeal Metastases | | 7/8/2025 - Provided Update
Plus Therapeutics, Inc. announced the treatment of its initial patients in the Company's ReSPECT-LM…
Full Summary |
ARWR Arrowhead Pharmaceuticals | $18.86
-0.1% | +12.7%
 | Zodasiran
For the Treatment of Homozygous Familial Hypercholesterolemia |
Phase 3 | 7/8/2025 - Dose Update
Arrowhead Pharmaceuticals, Inc. announced that it has dosed the first subject in the YOSEMITE Phase …
Full Summary |
BCLI Brainstorm Cell Therapeutics | $1.22
-1.6% | -1.6%
 | NurOwn
Progressive Multiple Sclerosis (MS) | | 7/8/2025 - Provided Update
BrainStorm Cell Therapeutics Inc today acknowledged that the U.S. Food and Drug Administration's (F…
Full Summary |
ITCI Intra-Cellular Therapies | $131.87
| | CAPLYTA (Lumateperone)
Depressive Episodes associated with Bipolar | supplemental New Drug Application (sNDA) | 7/8/2025 - sNDA Filing
Johnson & Johnson announced the submission of a supplemental New Drug Application (sNDA) to the U.S.…
Full Summary |
JNJ Johnson & Johnson | $157.72
+0.9% | +1.6%
 | CAPLYTA (Lumateperone)
Depressive Episodes associated with Bipolar | supplemental New Drug Application (sNDA) | 7/8/2025 - sNDA Filing
Johnson & Johnson announced the submission of a supplemental New Drug Application (sNDA) to the U.S.…
Full Summary |
ONCY Oncolytics Biotech | $1.12
-7.1% | +94.7%
 | Pelareorep
In Breast Cancer | | 7/8/2025 - Clinical Data
Oncolytics Biotech® Inc announced a strategic update highlighting its compelling clinical data from…
Full Summary |
MAT Mattel | $20.22
+0.4% | +5.0%
 | Barbie
type 1 diabetes (T1D) | | 7/8/2025 - Provided Update
Mattel, Inc announced that Barbie® is debuting the first Barbie doll with type 1 diabetes (T1D).
Full Summary |
RYTM Rhythm Pharmaceuticals | $89.04
+0.0% | +37.3%
| bivamelagon
In patients with acquired hypothalamic obesity. |
Phase 2 | 7/8/2025 - Provided Update
Rhythm Pharmaceuticals, Inc announced the Company will hold a conference call and webcast on Wednes…
Full Summary |
SLDB Solid Biosciences | $5.42
-1.8% | +17.6%
 | SGT-501
For the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT) |
IND | 7/8/2025 - FDA Approval
Solid Biosciences Inc. announced approval of its Investigational New Drug (IND) application by the …
Full Summary |
SLDB Solid Biosciences | $5.42
-1.8% | +17.6%
| SGT-501
For the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT) |
Phase 1b | 7/8/2025 - Clinical Trial
Solid expects to initiate Phase 1b clinical trial of SGT-501 in the fourth quarter of 2025 -
Full Summary |
KALV KalVista Pharmaceuticals | $15.51
-3.0% | +15.2%
 | sebetralstat
Therapy for hereditary angioedema (HAE). | | 7/7/2025 - FDA Approval
KalVista Pharmaceuticals, Inc announced that the U.S. Food and Drug Administration (FDA) has approv…
Full Summary |
TNXP Tonix Pharmaceuticals | $42.36
+10.4% | +12.3%
| TNX-801
Potential Vaccine to Prevent Mpox and Smallpox | | 7/7/2025 - Data Presentation
Tonix Pharmaceuticals announced that Sina Bavari, PhD, Executive Vice President of Infectious Diseas…
Full Summary |
NTRA Natera | $163.36
+1.0% | -2.0%
 | Latitude™
For Colorectal Cancer | | 7/7/2025 - Data
Natera, Inc announced data from a colorectal cancer (CRC) study of its tissue-free Latitude™ MRD as…
Full Summary |
BSX Boston Scientific | $103.80
+0.8% | +4.4%
 | FARAPULSE™
A nonthermal treatment in which electric fields selectively ablate heart tissue in patients with atrial fibrillation (AF). | | 7/7/2025 - FDA Approval
Boston Scientific Corporation announced that it has received U.S. Food and Drug Administration (FDA…
Full Summary |
BYSI BeyondSpring | $2.25
-2.6% | -22.7%
 | plinabulin
Patients with non-small cell lung cancer | | 7/7/2025 - Publication
BeyondSpring Inc. announced publication of a human clinical study in Med (Cell Press) demonstrating…
Full Summary |
COGT Cogent Biosciences | $10.85
+4.3% | +49.4%
 | bezuclastinib
In patients with non-advanced systemic mastocytosis | | 7/7/2025 - Top-line results
Cogent Biosciences, Inc. announced positive top-line results from the registration-directed Part 2 …
Full Summary |
OGN Organon & Co. | $10.03
+1.2% | -0.7%
 | VTAMA (tapinarof) cream
Plaque psoriasis | | 7/7/2025 - Recommendation
Organon announced that VTAMA® (tapinarof) cream, 1%,was granted a strong recommendation by the Ameri…
Full Summary |
JSPR Jasper Therapeutics | $3.55
-3.5% | -36.6%
 | Briquilimab
To address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU) | Phase 1b/2a | 7/7/2025 - Updated data
Jasper Therapeutics is reporting updated data from Company's BEACON Phase 1b/2a study of subcutaneo…
Full Summary |
ARTL Artelo Biosciences | $28.50
+31.9% | +295.8%
| ART12.11
For overcoming problematic drug properties which allows for precise control over purity, potency, and consistency. | | 7/7/2025 - Data Presentation
Artelo Biosciences announced the presentation of compelling new preclinical data on its Cannabidiol…
Full Summary |
URGN Urogen Pharma | $14.64
+6.0% | +100.5%
 | UGN-103
For Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer |
Phase 3 | 7/7/2025 - Enrollment Completion
UroGen Pharma Ltd. announced that it has completed patient enrollment in its Phase 3 UTOPIA clinica…
Full Summary |
DNLI Denali Therapeutics | $15.35
+2.3% | +1.1%
 | tividenofusp
For the treatment of Hunter syndrome (MPS II) | BLA | 7/7/2025 - FDA review
Denali Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for…
Full Summary |
DNLI Denali Therapeutics | $15.35
+2.3% | +1.1%
| tividenofusp
For the treatment of Hunter syndrome (MPS II) | BLA
Target date: 2026-01-05 | 7/7/2025 - PDUFA Date
Denali Therapeutics Inc. announced that The FDA granted the BLA Priority Review with a Prescription…
Full Summary |
KALA KALA BIO | $6.90
+9.5% | +57.5%
| KPI-012
Clinical diagnosis of PCED | | 7/7/2025 - Provided Update
KALA BIO, Inc. announced that the Company will host a webcast event with Key Opinion Leaders (KOLs…
Full Summary |
AGEN Agenus | $5.92
+14.3% | +14.7%
| BOT/BAL
In Metastatic MSS Colorectal Cancer |
Phase 3 | 7/7/2025 - Provided Update
Agenus also confirmed that it has reached agreement with the U.S. Food and Drug Administration (FDA)…
Full Summary |
FBIO Fortress Biotech | $1.99
| -5.2%
 | MB-101
Leptomeningeal brain tumors | Orphan Drug | 7/7/2025 - Designation Grant
Mustang Bio, Inc announced that the U.S. Food and Drug Administration ("FDA") has granted Orphan Dr…
Full Summary |
MBIO Mustang Bio | $2.68
-13.8% | +109.4%
 | MB-101
Leptomeningeal brain tumors | Orphan Drug | 7/7/2025 - Designation Grant
Mustang Bio, Inc announced that the U.S. Food and Drug Administration ("FDA") has granted Orphan Dr…
Full Summary |
IINN Inspira Technologies OXY B.H.N. | $1.37
-4.9% | +71.5%
 | ART100
Cardio-Pulmonary Bypass Device | | 7/7/2025 - Provided Update
Inspira™ Technologies OXY B.H.N. Ltd. announced that it is engaged in high-level talks with a gover…
Full Summary |
IMMX Immix Biopharma | $2.71
-1.5% | +11.5%
 | NXC-201
NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis. | | 7/7/2025 - Provided Update
Immix Biopharma, Inc. announced accelerated U.S. NEXICART-2 clinical trial progress in relapsed/ref…
Full Summary |
ASND Ascendis Pharma A/S | $176.49
+0.4% | +2.8%
 | TransCon PTH
Adult Hypoparathyroidism | | 7/7/2025 - Oral presentation
Ascendis Pharma A/S announced two oral presentations at ENDO 2025, the annual meeting of the Endoc…
Full Summary |
APGE Apogee Therapeutics | $38.57
+4.2% | -9.1%
 | APG777
For the Treatment for Atopic Dermatitis and Other Inflammatory Diseases |
Phase 2 | 7/6/2025 - Data
Apogee Therapeutics, Inc announced it will report Part A 16-week data from the Phase 2 APEX trial o…
Full Summary |
NVS Novartis | $123.69
+0.6% | +4.8%
 | secukinumab
In adults with newly diagnosed or relapsing giant cell arteritis (GCA). |
Phase 3 | 7/3/2025 - Top-line results
Novartis announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinu…
Full Summary |
BCAB BioAtla | $0.39
-0.3% | -16.4%
 | BA3182
In Patients with Treatment Refractory Metastatic Adenocarcinoma | | 7/3/2025 - Data Presentation
BioAtla, Inc today presented first-in-human data in a poster titled "Preliminary Results from a Fir…
Full Summary |
MIRA MIRA Pharmaceuticals | $1.20
+6.2% | -0.8%
 | MIRA-55
Potential treatment for anxiety and cognitive decline. | | 7/3/2025 - Preclinical Data
MIRA Pharmaceuticals, Inc. announced positive preclinical data demonstrating that Mira-55, the Com…
Full Summary |
VRTX Vertex Pharmaceuticals | $479.53
+0.1% | +6.0%
 | exagamglogene autotemcel
For severe sickle cell disease | | 7/3/2025 - Positive Data
Vertex Pharmaceuticals announced positive longer-term data for PrCASGEVY® (exagamglogene autotemcel…
Full Summary |
BLTE Belite Bio | $62.03
-3.3% | +1.5%
 | Tinlarebant
In Stargardt Disease |
Phase 3 | 7/2/2025 - Enrollment Update
Belite Bio, Inc announced the completion of enrollment in the PHOENIX trial, a global, 24-month Phas…
Full Summary |
TIL Instil Bio | $26.76
+4.4% | -26.8%
 | AXN-2510
In Relapsed/Refractory Solid Tumors |
IND | 7/2/2025 - FDA Clearance
Instil Bio, Inc. announced the clearance of an Investigational New Drug (IND) application for AXN-25…
Full Summary |
MRK Merck & Co., Inc. | $84.06
+0.4% | +4.7%
| sotatercept-csrk
In adults with pulmonary arterial hypertension | BLA Priority Review | 7/2/2025 - FDA GRANT
Merck announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority r…
Full Summary |
MRK Merck & Co., Inc. | $84.06
+0.4% | +4.7%
| sotatercept-csrk
In adults with pulmonary arterial hypertension | BLA Priority Review
Target date: 2025-10-25 | 7/2/2025 - PDUFA Date
Merck announced that The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action date…
Full Summary |
CTSO Cytosorbents | $1.14
+2.7% | +4.6%
 | DrugSorb-ATR
Antithrombotic Removal System | | 7/2/2025 - Regulatory Update
CytoSorbents Corporation today provided a regulatory update on its marketing applications for DrugS…
Full Summary |
TNXP Tonix Pharmaceuticals | $42.36
+10.4% | +12.3%
| TNX-1700
Recombinant human TFF2-human serum albumin or HSA) for the treatment of colon and gastric cancers. | | 7/2/2025 - Publication
Tonix Pharmaceuticals Holding Corp announced the publication of a paper entitled, "A CXCR4 Partial…
Full Summary |
OGN Organon & Co. | $10.03
+1.2% | -0.7%
| OG-6219
In Patients with Endometriosis-Related Pain |
Phase 2 | 7/2/2025 - Endpoint Missed
Organon announced that the Phase 2 ELENA proof-of-concept study evaluating the investigational cand…
Full Summary |
VYNE VYNE Therapeutics | $1.38
-4.2% | +49.7%
 | VYN202
A Novel BD2-Selective BET Inhibitor |
Phase 1b | 7/2/2025 - Provided Update
VYNE Therapeutics Inc today provided a program update for VYN202 following the clinical hold issue…
Full Summary |
CERS Cerus | $1.55
+4.0% | +9.2%
 | INTERCEPT Blood System
for platelets, plasma, IFC, and red blood cells | | 7/2/2025 - Regulatory Update
Cerus Corporation announced a European regulatory update on the INTERCEPT RBC program.
Full Summary |
IINN Inspira Technologies OXY B.H.N. | $1.37
-4.9% | +71.5%
| ART100
Cardio-Pulmonary Bypass Device | | 7/2/2025 - Provided Update
Inspira™ Technologies OXY B.H.N. Ltd. announced it has secured a binding $22.5 million purchase or…
Full Summary |
REGN Regeneron Pharmaceuticals | $559.76
+1.3% | +7.9%
 | linvoseltamab-gcpt
For Treatment of Relapsed or Refractory Multiple Myeloma | | 7/2/2025 - FDA GRANT
Regeneron Pharmaceuticals, Inc announced that the U.S. Food and Drug Administration (FDA) has grant…
Full Summary |
IMAB I-Mab | $2.05
-11.3% | -17.7%
 | Givastomig
In patients with advanced cancers |
Phase 1b | 7/2/2025 - Positive Data
I-Mab announced the presentation of positive Phase 1b combination data for givastomig, in combinati…
Full Summary |
IVA Inventiva | $3.31
-1.9% | -6.6%
 | Lanifibranor
Nonalcoholic steatohepatitis (NASH) |
Phase 2b | 7/2/2025 - Publication
Inventiva announces the publication in Journal of Hepatology Reports, a peer-reviewed, scientific jo…
Full Summary |
FDMT 4D Molecular Therapeutics | $4.35
-1.6% | -0.2%
 | 4D-150
Intravitreal vector, R100, and a transgene payload that expresses both aflibercept and a VEGF-C inhibitory RNAi. |
Phase 3 | 7/2/2025 - Provided Update
4D Molecular Therapeutics announced the acceleration of the 4D-150 4FRONT Phase 3 program in wet ag…
Full Summary |
ATAI atai Life Sciences | $2.73
+2.6% | +22.4%
 | BPL-003
In Patients With Treatment Resistant Depression |
Phase 2b | 7/1/2025 - Top-line results
atai Life Sciences and Beckley Psytech Limited jointly announced positive topline results from the…
Full Summary |
NVCR NovoCure | $18.46
+1.5% | +6.3%
 | Tumor Treating Fields - PANOVA-3
Locally advanced pancreatic cancer |
Phase 3 | 7/1/2025 - Results
Novocure announced that it will present the final secondary endpoint results from the Phase 3 PANOV…
Full Summary |
BTAI BioXcel Therapeutics | $2.00
+0.3% | +11.7%
 | BXCL501 (SERENITY)
Schizophrenia and bipolar disorders | | 7/1/2025 - Recommendation
BioXcel Therapeutics announced the second positive recommendation by an independent Data Safety Moni…
Full Summary |
BTAI BioXcel Therapeutics | $2.00
+0.3% | +11.7%
| BXCL501 (SERENITY)
Schizophrenia and bipolar disorders | Target date: 2025-Q3 | 7/1/2025 - Top-line data
BioXcel Therapeutics, Inc announced that Topline data expected in Q3 2025.
Full Summary |
